Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Combination Chemotherapy in Treating Young Male Patients With Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: prednisone
Drug: vinblastine sulfate
Drug: vincristine sulfate
Radiation: radiation therapy

First Posted Date: 2006-11-10

Last Posted Date: 2020-03-26

Lead Sponsor: Christine Mauz-Körholz

Target Recruit Count: 16

Registration Number: NCT00398554

Locations: 🇨🇭
University Children's Hospital, Zurich, Switzerland
🇩🇪
Medizinische Hochschule Hannover, Hannover, Germany
🇩🇪
Klinikum Augsburg, Augsburg, Germany

and more 8 locations

Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors

Phase 3

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: carboplatin
Drug: temozolomide
Drug: cisplatin
Drug: thiotepa
Drug: cyclophosphamide
Drug: vincristine sulfate
Drug: etoposide
Procedure: autologous bone marrow transplantation
Drug: methotrexate
Procedure: autologous hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy

First Posted Date: 2006-10-26

Last Posted Date: 2013-12-18

Lead Sponsor: Children's Hospital Los Angeles

Target Recruit Count: 120

Registration Number: NCT00392886

Locations: 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇦🇺
Princess Margaret Hospital for Children, Perth, Western Australia, Australia
🇺🇸
Children's Hospital of Orange County, Orange, California, United States

and more 34 locations

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Biological: pegfilgrastim
Biological: rituximab
Drug: cyclophosphamide
Drug: cytarabine
Drug: etoposide
Drug: doxorubicin hydrochloride
Drug: ifosfamide
Drug: liposomal cytarabine
Drug: leucovorin calcium
Drug: methotrexate
Drug: therapeutic hydrocortisone
Drug: vincristine sulfate

First Posted Date: 2006-10-26

Last Posted Date: 2018-06-06

Lead Sponsor: AIDS Malignancy Consortium

Target Recruit Count: 34

Registration Number: NCT00392834

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles, California, United States
🇺🇸
Floyd and Delores Jones Cancer Institute at Virginia Mason Medical Center, Seattle, Washington, United States

and more 10 locations

Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Small Cell Lung Cancer

Interventions: Drug: Amrubicin
Drug: Cisplatin
Drug: Etoposide

First Posted Date: 2006-10-17

Last Posted Date: 2019-11-19

Lead Sponsor: Celgene

Target Recruit Count: 99

Registration Number: NCT00388960

Locations: 🇳🇱
Academisch Medisch Centrum, Amsterdam, Netherlands
🇳🇱
Medisch Spectrum Twente - Dept of Pulmonary Diseases, Enschede, Netherlands
🇳🇱
Academisch Ziekenhuis Maastricht, Maastricht, Netherlands

and more 22 locations

Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease

Phase 2

Completed

Conditions: Hodgkin Disease
Hodgkin's Lymphoma
Lymphoma

Interventions: Drug: Gemcitabine
Drug: Vinorelbine
Drug: Carmustine
Drug: Etoposide
Drug: Cyclophosphamide
Procedure: Autologous HCT

First Posted Date: 2006-10-16

Last Posted Date: 2017-06-14

Lead Sponsor: Stanford University

Target Recruit Count: 146

Registration Number: NCT00388349

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Bevacizumab, Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2006-10-13

Last Posted Date: 2015-04-28

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 79

Registration Number: NCT00387699

Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Phase 3

Completed

Conditions: L1 Childhood Acute Lymphoblastic Leukemia
L2 Childhood Acute Lymphoblastic Leukemia
B-cell Childhood Acute Lymphoblastic Leukemia
Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia

Interventions: Drug: vincristine sulfate
Drug: prednisone
Drug: doxorubicin hydrochloride
Drug: pegaspargase
Drug: cytarabine
Drug: methotrexate
Drug: dexamethasone
Drug: etoposide
Drug: cyclophosphamide
Drug: leucovorin calcium
Biological: filgrastim
Drug: asparaginase
Drug: mercaptopurine

First Posted Date: 2006-09-28

Last Posted Date: 2024-03-26

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 275

Registration Number: NCT00381680

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
🇺🇸
Childrens Memorial Hospital, Chicago, Illinois, United States

and more 170 locations

Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma

Phase 3

Conditions: Sarcoma

First Posted Date: 2006-09-21

Last Posted Date: 2013-08-12

Lead Sponsor: European Paediatric Soft Tissue Sarcoma Study Group

Target Recruit Count: 600

Registration Number: NCT00379457

Locations: 🇸🇪
Uppsala University Hospital, Uppsala, Sweden
🇩🇰
Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
🇮🇪
Our Lady's Hospital for Sick Children Crumlin, Dublin, Ireland

and more 23 locations

Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

Phase 3

Active, not recruiting

Conditions: Stage III Kidney Wilms Tumor
Stage IV Kidney Wilms Tumor

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Procedure: Conventional Surgery
Drug: Cyclophosphamide
Biological: Dactinomycin
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Drug: Vincristine Sulfate Liposome

First Posted Date: 2006-09-21

Last Posted Date: 2024-04-16

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 395

Registration Number: NCT00379340

Locations: 🇺🇸
Saint Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
🇺🇸
Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
🇺🇸
Rainbow Babies and Childrens Hospital, Cleveland, Ohio, United States

and more 224 locations

Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 3

Completed

Conditions: Leukemia

Interventions: Drug: asparaginase
Drug: cytarabine
Drug: daunorubicin hydrochloride
Drug: etoposide
Drug: gemtuzumab ozogamicin
Drug: mitoxantrone hydrochloride

First Posted Date: 2006-09-07

Last Posted Date: 2021-03-24

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 1070

Registration Number: NCT00372593

Locations: 🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States
🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

and more 195 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy